Brief: Sensorion/Sens-401: First Patient Enrolled In Phase 2A Proof Of Concept Clinical Trial In Cisplatin-Induced Ototoxicity

Sensorion SA

03/01/2023 06:32

Jan 3 (Reuters) - Sensorion Sa  ALSEN.PA :
    * SENSORION ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2A
PROOF OF
CONCEPT CLINICAL TRIAL OF SENS-401 IN CISPLATIN-INDUCED
OTOTOXICITY
    * INDICATION REPRESENTS A VERY SIGNIFICANT UNMET NEED FOR
PATIENTS
AND IS A LARGE POTENTIAL MARKET WITH AN ESTIMATED INCIDENCE OF
MORE THAN 500,000 PATIENTS IN UNITED STATES, EUROPEAN UNION AND
JAPAN
    * SENSORION ANTICIPATES PUBLICATION OF INTERIM DATA IN H1
2023

Source text for Eikon:  ID:nBw2dH5kca 
Further company coverage:  ALSEN.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))